The use of sodium-glucose co-transporter type II (SGLT2) inhibitors in patients with chronic heart failure against the background of type 2 diabetes mellitus

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of hospitalization for heart failure in large studies of patients with type 2 diabetes mellitus (DM2); chronic heart failure (CHF) with reduced left ventricular ejection fraction; and patients after percutaneous coronary intervention. This review analyzes the results of large randomized clinical trials that assess the effectiveness and safety of SGLT2 inhibitors in DM2 patients with varying degrees of CHF.

Full Text

Restricted Access

About the authors

V. I. Petrov

Volgograd State Medical University

Email: marusya8906@mail.ru
ORCID iD: 0000-0001-5177-846X
SPIN-code: 2224-5311
Scopus Author ID: 148296
Russian Federation, Volgograd

O. V. Shatalova

Volgograd State Medical University

Email: marusya8906@mail.ru
ORCID iD: 0000-0002-7311-4549
SPIN-code: 3783-6286
Scopus Author ID: 478471
Russian Federation, Volgograd

Maria S. Klykova

Volgograd State Medical University

Author for correspondence.
Email: marusya8906@mail.ru

Teaching Assistant, Professor, Department of Clinical Pharmacology and Intensive Care

Russian Federation, Volgograd

N. P. Stetsky

Volgograd State Medical University

Email: marusya8906@mail.ru
ORCID iD: 0000-0002-6721-7453
Russian Federation, Volgograd

References

  1. Ambrosio A.P.; Fonarev G.K.; Butler J.; et al. Global medical and economic burden of hospitalizations for heart failure: lessons learned from the registers of hospitalized patients with heart failure. J Call Cardiol. 2014;63(12):1123–33. doi: 10.1016/j.jacq.2013.11.053.
  2. Bluming G.S.; Knetsch A.M.; Sturkenbum M.J.; et al. Quantification of the heart failure epidemic: prevalence; morbidity; lifetime risk and prognosis of heart failure: Rotterdam Study. Eur Heart J. 2004;25(18):1614–19. doi: 10.1016/j.hj.2004.06.038.
  3. Mostert A.; Hauz A.V. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–46. doi: 10.1136/hrt.2003.025270.
  4. van Riet E.E.; Hoes A.V.; Wagenaar K.P.; et al. Epidemiology of heart failure: prevalence of heart failure and ventricular dysfunction in the elderly over time. Systematic review. Eur J Heart failure. 2016;18(3):242–52. doi: 10.1002/ejhf.483.
  5. Beggs S.A.S.; McDonagh Th.A.; Gardner R.S. Chronic heart failure: epidemiology; investigation and management. Medicine. 2022;50(8):479–86. doi: 10.1016/j.mpmed.2022.05.002.
  6. Поляков Д.С.; Фомин И.В.; Беленков Ю.Н. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021;61(4):4–14 doi: 10.18087/cardio.2021.4.n1628. [Polyakov D.S.; Fomin I.V.; Belenkov Yu.N.; et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiya. 2021;61(4):4–14. (In Russ.)].
  7. Raphael C.; Briscoe C.; Davies J.; et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Published on-line. 2006;27. doi: 10.1136/hrt.2006.089656.
  8. Echouffo-Tcheugui J.B.; Xu H.; DeVore A.D.; et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. Am Heart J. 2016;182:9–20. doi: 10.1016/j.ahj.2016.07.025.
  9. Дедов И.И.; Шестакова М.В.; Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова; М.В. Шестаковой; А.Ю. Майорова; 8-й выпуск. Сахарный диабет. 2017;20(Suppl. 1):1–121. [Dedov I.I.; Shestakova M.V.; Majorov A.Yu.; et al. Algorithms of specialized medical care for patients with diabetes mellitus. Ed. I.I. Dedova; M.V. Shestakova; A.Yu. Mayorova; 8th issue. Diabetes Mellitus. 2017;20(Suppl. 1):1–121. (In Russ.)].
  10. Fonarow G.C. Diabetes medications and heart failure: recognizing the risk. Circulation. 2014;130(18):1565–67. doi: 10.1161/CIRCULATIONAHA.114.012883.
  11. Solomon S.D.; de Boer R.A.; DeMets D.; et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23(7):1217–25. doi: 10.1002/ejhf.2249.
  12. Docherty K.F.; Simpson J.; Jhund P.S.; et al. DAPA-HF Investigators and Committees. Effect of Dapagliflozin; Compared With Placebo; According to Baseline Risk in DAPA-HF. JACC Heart Fail. 2022;10(2):104–18. doi: 10.1016/j.jchf.2021.09.002.
  13. Zinman B.; Wanner C.; Lachin J.M.; et al. EMPA-REG OUTCOME Investigators. Empagliflozin; Cardiovascular Outcomes; and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28. doi: 10.1056/NEJMoa1504720.
  14. von Lewinski D.; Kolesnik E.; Tripolt N.J.; et al.; on behalf of the EMMY Investigators. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43(41):4421–32. doi: 10.1093/eurheartj/ehac494.
  15. Zinman B.; Wanner C.; Lachin J.M.; et al. EMPA‐REG OUTCOME Investigators. Empagliflozin; cardiovascular outcomes; and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
  16. Neal B.; Perkovic V.; Mahaffey K.W.; et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.
  17. Wiviott S.D.; Raz I.; Bonaca M.P.; et al. DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.
  18. Santos Gallego C.G.; Vargas Delgado A.P.; Requena Ibanez J.A.; et al. EMPA TROPISM (ATRU 4) Investigators. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77:243–55.
  19. Lee M.M.Y.; Brooksbank K.J.M.; Wetherall K.; et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes; or prediabetes; and heart failure with reduced ejection fraction (SUGAR DM HF). Circulation. 2021;143:516–25.
  20. Omar M.; Jensen J.; Ali M.; et al. Associations of empagliflozin with left ventricular volumes; mass; and function in patients with heart failure and reduced ejection fraction: a substudy of the Empire HF randomized clinical trial. JAMA Cardiol. 2021. Jan 6. 10.1001/jamacardio.2020.6827.
  21. Jhund P.S.; Kondo T.; Butt J.H.; et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level; pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28:1956–64. doi: 10.1038/s41591-022-01971-4.
  22. Tripolt N.J.; Kolesnik E.; Pferschy P.N.; et al. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial. Am Heart J. 2020;221:39–47.
  23. Aziri B.; Begic E.; Jankovic S.; et al. Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events. ESC Heart Failure. 2023. doi: 10.1002/ehf2.14355.
  24. McDonagh Th.A.; Metra M.; Adamo M.; et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–39. doi: 10.1093/eurheartj/ehad195.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.1.

Download (273KB)
Indexing metadata

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies